Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Sector ...

Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the last few decades with several ASO-based ...

More generic drug prices decreased than increased in January, while nearly 1,000 brand-name drugs saw their prices increase ...

Merck KGaA CEO Belén Garijo says Trump's China tariffs impact manageable due to regionalized supply chains; company reports 2 ...

The global gene therapy market is projected to grow from $8.85 billion in 2024 to $36.55 billion by 2032, at a CAGR of 19.4%.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies ...

Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only ...

A new article in the journal Nucleic Acid Therapeutics addresses the recognition by the U.S. Food and Drug Administration ...

Oligonucleotide API MarketThe global oligonucleotide API market is poised to grow from USD 2.81 billion in 2024 to USD 4.84 billion by 2034, expanding at a CAGR of 5.60%. The increasing need for ...

This synthesis involved individually adding nucleotides to a chain, and back then, we did it manually, so it took more time. However, one group developed dimers of some of these bases that could save ...

Welcome to the Codexis fourth quarter and full year 2024 Earnings conference call. (Operator Instructions) Please note that this event is being recorded. And now, I’ll turn the call over to Carrie ...

In December 2024, Praxis received Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for relutrigine for Dravet Syndrome. This is the third RPDD for relutrigine ...